LifeArc
Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease
Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease
UK researchers uncover first new asthma and COPD attack treatment in 50 years
The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings
Researchers develop new approach to target cells affected by motor neurone disease
The technique could lead to safer and more effective gene therapies for the neurodegenerative disease
LifeArc and King’s College London partner to accelerate treatment for motor neurone disease
The rare neurodegenerative disease affects one in every 300 people in the UK
LifeArc launches £5m motor neurone disease drug repurposing programme
Research teams will be eligible to receive up to £750,000 per project through the programme
New UK research institute launched for motor neurone disease
The research institute will bring together MND labs, clinical centres and researchers
NIHR partners with Motor Neurone Disease Association for MND research
The partnership will speed up the discovery of treatments and insights for MND
LSTM and LifeArc announce partnership and research fund to tackle infectious diseases
The research responds to a need for new treatments and diagnostic technologies
Innovate UK awards Sano Genetics £330,000 grant for ALS study
The project will chart the psychological impacts of having a genetic predisposition to ALS
LifeArc launches rare disease programme with £100m investment
An initial £40m will go towards the creation of up to five rare disease research centres
UK Government commit £50m to motor neurone disease research
The pledged funding is being placed into the hands of researchers ‘as quickly as possible’
Verge Genomics begins human trials with AI-sourced ALS drug
VRG50635 was discovered by the company’s all-in-human, AI-powered platform